The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Tevimbra (tislelizumab) for resectable non-small cell lung cancer (NSCLC).  It is recommended in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for adult patients at high risk of recurrence.   Dr […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!